The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers

Danny Vesprini, Steven A. Narod, John Trachtenberg, Juanita Crook, Farid Jalali, John Preiner, Srikala Sridhar, Robert G. Bristow

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science